Lumos Pharma, Inc. (LUMO): Price and Financial Metrics

Lumos Pharma, Inc. (LUMO): $7.70

-0.01 (-0.13%)

POWR Rating

Component Grades













Add LUMO to Watchlist
Sign Up

Industry: Biotech



in industry

LUMO Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for LUMO is 0 -- better than merely 6.24% of US stocks.
  • The ratio of debt to operating expenses for Lumos Pharma Inc is higher than it is for about merely 6.64% of US stocks.
  • LUMO's price/sales ratio is 358.33; that's higher than the P/S ratio of 98.98% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Lumos Pharma Inc are BYSI, RDUS, INSM, INFN, and KPTI.
  • LUMO's SEC filings can be seen here. And to visit Lumos Pharma Inc's official web site, go to

LUMO Valuation Summary

  • In comparison to the median Healthcare stock, LUMO's price/sales ratio is 6344.93% higher, now standing at 731.5.
  • Over the past 119 months, LUMO's price/sales ratio has gone up 681.4.
  • Over the past 119 months, LUMO's EV/EBIT ratio has gone up 7.9.

Below are key valuation metrics over time for LUMO.

Stock Date P/S P/B P/E EV/EBIT
LUMO 2021-08-31 731.5 0.9 -5.1 0.7
LUMO 2021-08-30 715.3 0.9 -4.9 0.7
LUMO 2021-08-27 708.9 0.9 -4.9 0.8
LUMO 2021-08-26 683.9 0.8 -4.7 0.9
LUMO 2021-08-25 671.0 0.8 -4.6 1.0
LUMO 2021-08-24 644.4 0.8 -4.5 1.1

LUMO Growth Metrics

    Its 2 year cash and equivalents growth rate is now at -40.36%.
  • Its 2 year price growth rate is now at -70.56%.
  • Its 5 year price growth rate is now at -90.63%.
LUMO's revenue has moved down $2,450,000 over the prior 34 months.

The table below shows LUMO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 0.23 -29.648 -30.43
2021-09-30 0.05 -30.8 -27.204
2021-06-30 0.124 -23.368 -17.951
2021-03-31 0.147 -30.099 -14.634
2020-12-31 0.168 -22.997 -6.314
2020-09-30 0.561 -24.048 -12.17

LUMO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LUMO has a Quality Grade of D, ranking ahead of 21.86% of graded US stocks.
  • LUMO's asset turnover comes in at 0.001 -- ranking 434th of 681 Pharmaceutical Products stocks.
  • INVA, RETA, and SUPN are the stocks whose asset turnover ratios are most correlated with LUMO.

The table below shows LUMO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.001 1 -1.992
2021-03-31 0.001 1 -0.861
2020-12-31 0.001 1 -0.498
2020-09-30 0.004 1 -0.644
2020-06-30 0.005 1 -1.373
2020-03-31 0.007 1 -2.610

LUMO Price Target

For more insight on analysts targets of LUMO, see our LUMO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $27.00 Average Broker Recommendation 1.42 (Moderate Buy)

LUMO Stock Price Chart Interactive Chart >

Price chart for LUMO

LUMO Price/Volume Stats

Current price $7.70 52-week high $11.52
Prev. close $7.71 52-week low $6.15
Day low $7.50 Volume 2,900
Day high $7.80 Avg. volume 19,402
50-day MA $7.80 Dividend yield N/A
200-day MA $8.55 Market Cap 64.44M

Lumos Pharma, Inc. (LUMO) Company Bio

Lumos Pharma, Inc. operates as a biopharmaceutical company. The Company discovers, develops, and commercializes therapeutics for patients and families living with rare diseases. Lumos Pharma operates worldwide.

LUMO Latest News Stream

Event/Time News Detail
Loading, please wait...

LUMO Latest Social Stream

Loading social stream, please wait...

View Full LUMO Social Stream

Latest LUMO News From Around the Web

Below are the latest news stories about Lumos Pharma Inc that investors may wish to consider to help them evaluate LUMO as an investment opportunity.

Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022

AUSTIN, Texas, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its full year 2021 financial results after market close on Thursday, March 10, 2022. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. There will be a question-and-answer session f

Yahoo | February 23, 2022

Great news for Lumos Pharma, Inc. (NASDAQ:LUMO): Insiders acquired stock in large numbers last year

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

Yahoo | February 14, 2022

Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

AUSTIN, Texas, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. Wainwright Virtual BIOCONNECT Conference being held January 10-13, 2022. A webcast of the presentation will be available at 7:00AM ET on January 10th through the following link: and on Lumos Pharma’s website in

Yahoo | January 5, 2022

Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ...

Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics Pharmaceuticals Inc, Amicus Therapeutics Inc, Merus NV, sells ESSA Pharma Inc, Seres Therapeutics Inc, CM Life Sciences Inc, Lumos Pharma Inc, Kezar Life Sciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Opaleye Management Inc..

Yahoo | December 28, 2021

Down 16.1% in 4 Weeks, Here's Why Lumos (LUMO) Looks Ripe for a Turnaround

Lumos (LUMO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | November 24, 2021

Read More 'LUMO' Stories Here

LUMO Price Returns

1-mo 0.13%
3-mo -16.58%
6-mo 11.11%
1-year -25.39%
3-year -39.75%
5-year -88.36%
YTD 11.11%
2021 -80.59%
2020 56.83%
2019 66.45%
2018 -81.26%
2017 -21.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4585 seconds.